Inventor · disambiguated record
Eswaraiah Sajja
Also filed as: SAJJA ESWARAIAH
17 granted patents·22 pending applications·17 citations·filing 2005–2023
88Inventor score
Files withMSN LABORATORIES PRIVATE LTD R&D CENTER19MSN LABORATORIES PRIVATE LTD5SAJJA ESWARAIAH5SRINIVASAN THIRUMALAI RAJAN3GORE SUBHASH P1
Top patents by PatentIndex Score
39 records- 0188US11261160B2Process for the preparation of N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide, (2S)-hydroxybutanedioate and its polymorphs thereofMSN LABORATORIES PRIVATE LTD R&D CENTER·Filed 2017·Granted Mar 1, 2022·9 cites·15 claims
- 0283US10550107B2Process for the preparation of N-[4-[(3-chloro-4-fluoro phenyl) amino]-7-[[(3s-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethyl amino)-(2E)-2-butenamide (2Z)-2-butenedioate (1:2) and its polymorphs thereofMSN LABORATORIES PRIVATE LTD·Filed 2016·Granted Feb 4, 2020·3 cites·20 claims
- 0369US7772398B2Process for making crystalline form I of clopidogrel hydrogen sulphateREDDYS LAB INC DR·Filed 2005·Granted Aug 10, 2010·2 cites·12 claims
- 0468US10913717B2Solid state forms of N-[2-[(I S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methyl sulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-L H-isoindol-4-yl]acetamide and process for preparation thereofMSN LABORATORIES PRIVATE LTD R&D CENTER·Filed 2019·Granted Feb 9, 2021·0 cites·13 claims
- 0567US7977478B2Polymorphic forms of vardenafilREDDYS LAB LTD DR·Filed 2006·Granted Jul 12, 2011·3 cites·6 claims
- 0662US2025074882A1Improved process for the preparation of 5-[(4-bromo-2-fluorophenyl)amino]-4-fluoro-n-(2hydroxyethoxy)-1-methyl-1h-benzimidazole-6-carboxamideMSN LABORATORIES PRIVATE LTD R&D CENTER·Filed 2023·Application pending·0 cites
- 0760US2025074912A1Improved process for the preparation of upadacitinibMSN LABORATORIES PRIVATE LTD R&D CENTER·Filed 2023·Application pending·0 cites
- 0859US10544097B2Solid state forms of N-[2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]acetamide and process for preparation thereofMSN LABORATORIES PRIVATE LTD·Filed 2016·Granted Jan 28, 2020·0 cites·6 claims
- 0959US2025136602A1Process for the preparation of a pure amorphous form of ubrogepantMSN LABORATORIES PRIVATE LTD F&D CENTER·Filed 2022·Application pending·0 cites
- 1058US2024327352A1Novel process for the preparation of 1-(2-{4-[(4-carbamoylpiperidin-1-yl)methyl]- n-methylbenzamido}ethyl)piperidin-4-yl n-({1,1'-biphenyl}-2-yl)carbamateMSN LABORATORIES PRIVATE LTD R&D CENTER·Filed 2022·Application pending·0 cites
- 1154US12227506B2Crystalline polymorphs of 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one and process for preparation thereofMSN LABORATORIES PRIVATE LTD R&D CENTER·Filed 2020·Granted Feb 18, 2025·0 cites·12 claims
- 1254US2025230160A1Process for the preparation of 4-((6br,10as)-3-methyl-2,3,6b,9,10,10a-hexahydro-1h,7h-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluoro-phenyl)-butan-1-one and intermediates thereofMSN LABORATORIES PRIVATE LTD R&D CENTER·Filed 2023·Application pending·0 cites
- 1353US2023233547A1Pharmaceutocal composition containing n-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-n?-(4-fluorophenly)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioateMSN LABORATORIES PRIVATE LTD R & D CENTER·Filed 2021·Application pending·0 cites
- 1452US12473292B2Polymorphs of 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl) pyridin-2-yl]-amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide and its pharmaceutically acceptable salts and process for the preparation thereofMSN LABORATORIES PRIVATE LTD R&D CENTER·Filed 2020·Granted Nov 18, 2025·0 cites·7 claims
- 1552US11149026B2Solid state forms of 5-chloro-6-[(2-iminopyrrolidin-1-yl)methyl]pyrimidine-2,4-(1H,3H)-dione hydrochloride and their processes for the preparation thereofMSN LABORATORIES PRIVATE LTD R&D CENTER·Filed 2018·Granted Oct 19, 2021·0 cites·13 claims
- 1652US2024300930A1Novel process for the preparation of 2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine-1-oxideMSN LABORATORIES PRIVATE LTD R&D CENTER·Filed 2022·Application pending·0 cites
- 1751US11434256B2Process for the preparation of 3α,7α-dihydroxy-6α-ethyl-5β-cholan-24-oic acidMSN LABORATORIES PRIVATE LTD R&D CENTER·Filed 2019·Granted Sep 6, 2022·0 cites·7 claims
- 1851US2024018152A1Novel process for the preparation of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide or its salts thereofMSN LABORATORIES PRIVATE LTD R&D CENTER·Filed 2022·Application pending·0 cites
- 1950US11236050B2Polymorphs of 4-[3-chloro-4-(n′-cyclopropyl ureido)phenoxy] -7-methoxyquinoline-6-carboxamide, its salts and process for the preparation thereofMSN LABORATORIES PRIVATE LTD R&D CENTER·Filed 2018·Granted Feb 1, 2022·0 cites·12 claims
- 2049US2022315605A1IMPROVED PROCESS FOR THE PREPARATON OF PURE (1'R,6R,6aR,7R,13S,14S,16R)-5-(ACETYLOXY)-3',4',6,6a,7,13,14,16-OCTAHYDRO-6',8,14-TRIHYDROXY-7',9-DIMETHOXY-4,10,23-TRIMETHYLSPIRO[6,16-(EPITHIOPROPANOXYMETH ANO)-7,13-IMINO-12H-1,3-DIOXOLO[7,8]ISOQUINO[3,2-b][3]BENZAZOCINE-20,1'(2'H)-ISOQUINOLIN]-19-ONE POLYMORPH THERE OFSRINIVASAN THIRUMALAI RAJAN·Filed 2020·Application pending·0 cites
- 2148US2007098788A1Non-benzodiazepine hypnotic compositionsGORE SUBHASH P·Filed 2006·Application pending·0 cites
- 2246US12227518B2Crystalline polymorphs of sodium (4R,12AS)-9-{[(2,4-difluorophenyl) methyl]carbamoyl}-4-methyl-6,8-dioxo-3,4,6,8,12,12A-hexahydro-2H-pyrido [1′,2′:4,5]pyrazino[2,1-b][1,3]oxazin-7-olate and process for preparation thereofMSN LABORATORIES PRIVATE LTD R&D CENTER·Filed 2020·Granted Feb 18, 2025·0 cites·16 claims
- 2346US2020306225A1Stable n-((1r,2r)-1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-1-hydroxy-3-(pyrrolidin-1-yl)propan-2-yl) octanamide (2r,3r)-2,3-dihydroxysuccinate premix and process for preparation thereofMSN LABORATORIES PRIVATE LTD R&D CENTER·Filed 2018·Application pending·0 cites
- 2446US2022251052A1Improved process for the preparation of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid or its pharmaceutically acceptable salts and polymorphs thereofMSN LABORATORIES PRIVATE LTD R&D CENTER·Filed 2020·Application pending·0 cites
- 2545US10865217B2Process for the preparation of 5-(4-cyanophenoxy)-1,3-dihydro-1-hydroxy-[2,1]-benzoxaborole and polymorphs thereofMSN LABORATORIES PRIVATE LTD R&D CENTER·Filed 2018·Granted Dec 15, 2020·0 cites·10 claims
- 2644US11279696B2Processes for the preparation of 7-{4-[4-(1-benzothiophen-4-yl) piperazin-1-yl]butoxy}quinolin-2(1H)-oneMSN LABORATORIES PRIVATE LTD·Filed 2017·Granted Mar 22, 2022·0 cites·4 claims
- 2744US2024279266A1An improved process for the preparation of (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl) oxolan-2-yl]-4-hydroxy-1,3-diazinan-2one and its intermediate compoundsMSN LABORATORIES PRIVATE LTD R&D CENTER·Filed 2022·Application pending·0 cites
- 2844US2023072265A1An improved process for the preparation of 4-({(1 r)-2-[5-(2-fluoro-3methoxyphenyl)-3-{[2-fluoro-6-(trifluoro methyl) phenyl]methyl}-4-methyl-2,6-dioxo-3,6dihydropyrimidin-1(2 h)-yl]-1-phenylethyl}amino)butanoic acid or its pharmaceutically acceptable saltsSRINIVASAN THIRUMALAI RAJAN·Filed 2020·Application pending·0 cites
- 2940US10913762B2Process for the preparation of D-glucitol, 1,5-anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl] oxy]phenyl] methyl] phenyl]-, (1S) and its crystalline forms thereofMSN LABORATORIES PRIVATE LTD·Filed 2017·Granted Feb 9, 2021·0 cites·17 claims
- 3037US2021163410A1An improved process for the preparation of (2s)-2-[(4r)-2-oxo-4-propyltetrahydro-1h-pyrrol-1-yl] butanamide and its intermediates thereofSRINIVASAN THIRUMALAL RAJAN·Filed 2018·Application pending·0 cites
- 3137US2021155651A1Process for the preparation of iron (iii) carboxymaltoseSRINIVASAN THIRUMALAI RAJAN·Filed 2019·Application pending·0 cites
- 3236US2005272787A1Process for preparing crystalline form A of valdecoxibSAJJA ESWARAIAH·Filed 2005·Application pending·0 cites
- 3335US2007225320A1Process for preparing clopidogrelSAJJA ESWARAIAH·Filed 2007·Application pending·0 cites
- 3434US8063214B2Polymorphic forms of tadalafilSAJJA ESWARAIAH·Filed 2005·Granted Nov 22, 2011·0 cites·9 claims
- 3533US10703731B2Process for the preparation of Trisodium (4- {[1S,3R)-1-([1,1′-biphenyl]-4-ylmethyl)-4-ethoxy-3-methyl-4-oxobutyl]amino}-4-oxobutanoate)-(N-petanoyl-N-{[2′-(1H-tetrazol-1-1D-5-yl)[1,1′-biphenyl]-4-yl]methyl}- L-valinate) and its polymorphs thereofMSN LABORATORIES PRIVATE LTD·Filed 2017·Granted Jul 7, 2020·0 cites·12 claims
- 3633US2007149779A1Primidone process and compositionsSAJJA ESWARAIAH·Filed 2006·Application pending·0 cites
- 3732US2020017483A1A process for the preparation of d-glucitol, 1,5-anhydro-1-c-[4-chloro-3-[[4- [[(3s)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-, ( 1 s)THIRUMALAI RAJAN SRINIVASAN·Filed 2018·Application pending·0 cites
- 3831US2019177281A1Process for the preparation of 5-[[[(2s)-2-amino-3-[4-(aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl] [(1s)-1-(4-phenyl-1h-imidazol-2-yl)ethyl]amino] methyl-2-methoxybenzoic acid and its polymorphs thereofTHIRUMALAI RAJAN SROMOVASAM·Filed 2017·Application pending·0 cites
- 3927US2007043088A1Process for preparing lacidipineSAJJA ESWARAIAH·Filed 2006·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Eswaraiah Sajja files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →